Allergan Biocell textured breast implant lawsuit MDL 2921: where the BIA-ALCL lymphoma litigation actually stands as bellwethers approach

The Allergan Biocell textured breast implant litigation represents one of the more procedurally complex active medical device mass torts due to its bifurcated MDL structure addressing both cancer and non-cancer injury claims. MDL 2921 (In re: Allergan Biocell Textured Breast Implant Products Liability Litigation), centralized in the U.S. District Court for the District of New Jersey before Judge Brian R. Martinotti and Magistrate Judge Joseph A. Dickson, consolidates approximately 1,481 federal cases as of early 2026. The defendants are Allergan plc and its parent company AbbVie (which acquired Allergan in May 2020), along with Allergan subsidiaries Inamed and McGhan that manufactured some of the recalled devices.

The substantive theory centers on breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) — a rare but serious cancer of the immune system that the World Health Organization has classified as a CD30-positive, ALK-negative T-cell lymphoma arising in the fibrous capsule surrounding breast implants rather than in breast tissue itself. BIA-ALCL is NOT breast cancer. The FDA first identified a possible association between breast implants and anaplastic large cell lymphoma in 2011 and refined its assessment in March 2018, estimating a lifetime risk between approximately 1 in 3,817 and 1 in 30,000. The critical fact for the Allergan litigation is that approximately 84% of worldwide BIA-ALCL cases have involved Allergan textured implants — with research showing an estimated sixfold higher BIA-ALCL risk for Biocell products compared to other textured implants.

The procedural posture has been substantially affected by the federal preemption defense. As Class III medical devices subject to FDA's Premarket Approval (PMA) process, breast implants fall under Riegel v. Medtronic, Inc., 552 U.S. 312 (2008), which held that the Medical Device Amendments to the Food, Drug, and Cosmetic Act preempt state law tort claims that impose requirements different from or in addition to those imposed by federal law for Class III PMA-approved devices. Allergan has aggressively pursued preemption defenses arguing that plaintiffs' claims challenge manufacturing processes and procedures the FDA has exclusive authority to review. Plaintiffs counter that their claims are based on Allergan's failure to comply with FDA-imposed PMA requirements rather than imposing additional requirements, an approach that survives Riegel preemption under subsequent case law.

This is the science behind the BIA-ALCL theory, the procedural history of MDL 2921 through the bifurcated track structure, the eligibility framework for current and prospective plaintiffs, the bellwether trial schedule, and the strategic considerations for affected patients navigating the complex preemption issues and bifurcated procedural framework.

What Biocell textured breast implants are and the alleged defect

Breast implants come in two main surface types:

Smooth implants. Have smooth surfaces with no texture. Standard since the early days of breast implantation. Most common type historically.

Textured implants. Have textured/rough surfaces designed to:

Reduce capsular contracture (scar tissue squeezing the implant)
Help the implant stay in position
Provide more realistic shape for anatomical implants
Allow tissue to adhere to the implant surface

Textured implants represented a small fraction of overall breast implant usage in the U.S. compared to other countries where textured implants were more common.

The Biocell texturing process. Allergan's Biocell implants used a specific salt-loss process to create the textured surface:

More aggressive texturing than other textured implants
Created larger pores in the silicone surface
Higher surface area than other texturing methods
Theoretical theory was better tissue integration

The BIA-ALCL mechanism. The current scientific understanding (still developing):

Texturing creates inflammation in surrounding tissue
Bacterial biofilm formation on textured surface
Chronic inflammation causes immune system response
T-cells in the area undergo malignant transformation
BIA-ALCL develops in the fibrous capsule
Cancer can spread if not detected and treated

Specific recalled products. The July 2019 worldwide recall included:

Saline implants: Natrelle Saline-Filled Breast Implants styles 168, 363, 468
Silicone 410 series: Natrelle and McGhan Silicone-Filled Breast Implants 410 styles (LL, LM, LF, LX, ML, MM, MF, MX, FL, FM, FF, FX)
410 Soft Touch series: Soft Touch styles in same configurations
INSPIRA series: Natrelle INSPIRA Breast Implants (TRL, TRLP, TRM, TRF, TRX, TSL, TSLP, TSM, TSF, TSX, TCL, TCLP, TCM, TCF, TCX)
Tissue expanders: Style 133 Biospan Tissue Expander and similar products

Internal corporate knowledge. Discovery has produced internal Allergan documents about Biocell risks:

Knowledge of disproportionate BIA-ALCL reports from Biocell products
Awareness of international regulatory actions before U.S. action
Internal safety surveillance data
Adverse event reporting analysis

The alleged injuries

Plaintiffs in MDL 2921 allege various injuries on two distinct tracks:

Cancer track: BIA-ALCL

Primary symptoms of BIA-ALCL:

Persistent swelling around breast implant
Pain in breast or implant area
Lumps in breast or armpit
Fluid collection (seroma) around implant
Capsular contracture
Skin changes around implant area
Asymmetry between breasts

Diagnosis:

Cytology of fluid collection (seroma fluid analysis)
Pathology of capsule tissue
CD30 immunohistochemistry positive
ALK immunohistochemistry negative
Imaging studies (MRI, CT, PET)

Treatment:

Surgical removal of implant and surrounding scar capsule (en bloc capsulectomy)
If cancer hasn't spread: surgery alone often curative
If spread: chemotherapy and possibly radiation
Treatment costs typically $10,000-$50,000+ for surgery, $100,000-$300,000+ for advanced disease
Some cases prove fatal — FDA has attributed 12+ deaths to Allergan Biocell

Long-term implications:

Need for ongoing cancer surveillance
Potential for recurrence
Psychological impact of cancer diagnosis
Quality of life impact

Non-cancer track: Systemic injuries

Approximately 350 non-BIA-ALCL cases in the MDL involve allegations of:

Chronic systemic symptoms ("breast implant illness")
Autoimmune disease manifestations
Connective tissue disorders
Capsular contracture and revision surgery needs
Seroma without cancer
Implant rupture
Performance failure
Chronic pain

The non-cancer track operates under different evidentiary standards and procedural framework than the BIA-ALCL track, reflecting the different scientific and legal issues involved.

Prophylactic removal cases

Some plaintiffs received Allergan Biocell implants and had them removed prophylactically due to:

Cancer risk concerns
Recall information
Healthcare provider recommendation
Personal concerns about retained implants

These cases allege different damages:

Cost of removal/revision surgery
Pain and suffering from additional surgery
Cost of replacement implants
Continuing surveillance costs
Allergan's "warranty" only covered free replacement with smooth implants, not removal costs

The procedural history of MDL 2921

The litigation has developed:

May 10, 2000. FDA approved Biocell textured breast implants for U.S. market.

June 2011. FDA first identified possible association between breast implants and anaplastic large cell lymphoma. Issued early safety communication.

March 2018. FDA refined assessment and acknowledged measurable lifetime risk associated with textured implants. Cited 1 in 3,817 to 1 in 30,000 risk estimates.

December 2018. Sales of Allergan textured breast implants suspended throughout European Union, Australia, Israel, and Brazil — substantial international action before U.S. regulators acted.

May 28, 2019. Health Canada suspended Allergan's Biocell licenses. International regulators acted nearly two months before FDA.

July 24, 2019. FDA requested Allergan voluntary recall of Natrelle Biocell textured breast implants and tissue expanders. Allergan initiated worldwide recall.

December 18, 2019. Judicial Panel on Multidistrict Litigation established MDL 2921 in the District of New Jersey. Judge Brian R. Martinotti assigned to oversee.

2020-2023. Active discovery, motion practice, and case management. Substantial Allergan internal document production. Bifurcated track structure established separating cancer and non-cancer claims.

2024. Master Long Form Personal Injury Complaint filed for BIA-ALCL track. Consolidated Class Action Complaint also filed.

2025. Allergan filed motion to dismiss based on preemption, citing Illinois state court precedent. Plaintiffs opposed dismissal. Mediation sessions in November 13, 2025 and December 8, 2025.

October 10, 2025. Case Management Order No. 36 addressed approximately 350 cases not involving BIA-ALCL or explant/revision surgery — separate procedural track for these systemic injury cases.

Late 2025. Case Management Order No. 37 set bellwether trial schedule.

February 6, 2026. Fact discovery deadline for first six bellwether cases.

June 15, 2026. FIRST BELLWETHER TRIAL SCHEDULED. Specific case to be selected from bellwether pool.

Five additional bellwether trials scheduled through subsequent dates extending into 2027.

The bifurcated structure means:

BIA-ALCL track has its own expert discovery and procedural framework
Non-cancer systemic injury track operates separately with different evidentiary standards
Discovery scope, motion practice, and case development differ between tracks

The preemption defense and case theory

Federal preemption is the central legal issue:

Medical Device Amendments preemption. Under 21 U.S.C. §360k, the Medical Device Amendments to the Food, Drug, and Cosmetic Act preempt state law requirements that are "different from, or in addition to" any FDA requirement applicable to the device.

Riegel v. Medtronic (2008). Supreme Court held that PMA-approved Class III medical devices receive substantial preemption protection. State law product liability claims that would impose additional or different requirements are preempted.

Plaintiff workaround: parallel claims. Subsequent case law has allowed "parallel claims" that don't impose different requirements but enforce existing FDA requirements:

Claims based on manufacturer's failure to comply with FDA-imposed PMA conditions
Claims based on FDA's specific requirements that manufacturer violated
Adverse event reporting compliance failures
Manufacturing process compliance failures

Allergan's defense. Allergan argues that plaintiffs' claims challenge:

FDA-approved design specifications
FDA-approved warnings and labeling
FDA-approved manufacturing processes

If accepted, this argument would substantially preempt most state law tort claims.

Plaintiffs' response. Plaintiffs argue their claims are based on:

Allergan's failure to comply with FDA-imposed post-market surveillance requirements
Allergan's adverse event reporting failures
Allergan's failure to update FDA on emerging risks
Manufacturing process deviations from FDA-approved specifications

These claims, if properly framed, survive Riegel preemption under subsequent case law.

State court precedent (Illinois). Allergan has cited an Illinois state court decision dismissing claims on preemption grounds. The federal MDL may follow or distinguish this precedent.

Critical issue going into bellwethers. The preemption ruling will substantially affect the litigation's trajectory. Strong preemption application could end most claims. Limited preemption application would allow substantive case theories to proceed.

Eligibility framework

The framework for filing Allergan claims:

Documented Biocell implant. Records showing the claimant received an Allergan Biocell textured breast implant:

Operative report from implantation surgery
Implant card (if provided to patient)
Hospital records identifying the specific Allergan product (specific style and lot number)
Surgeon records
Recall notification (if received)

Patient identification. Some patients don't know whether their implants are textured or smooth, or whether they're Biocell or different products. Resources for identification:

Original implantation surgeon
Hospital medical records
Pre-2019 implantation records
Recall notification letters

For BIA-ALCL track:

BIA-ALCL diagnosis required:

Pathology confirming CD30+, ALK- T-cell lymphoma
Documentation of textured implant association
Treatment records (surgery, chemotherapy, radiation as applicable)
Recurrence documentation if applicable

Strong BIA-ALCL case profile:

Allergan Biocell implant documented
BIA-ALCL diagnosed
Comprehensive treatment records
Substantial damages (medical expenses, lost wages, quality of life impact)
Some BIA-ALCL cases have proven fatal — wrongful death claims for surviving family

For non-cancer track:

Systemic injury documentation:

Allergan Biocell implant documented
Clinical symptoms consistent with breast implant illness
Medical evaluation supporting causation
Treatment records
Symptom improvement after explant (where applicable)

For prophylactic removal cases:

Allergan Biocell implant documented
Documented removal/explant surgery
Cost documentation
Reasonable basis for prophylactic removal (recall, healthcare provider recommendation)

Statute of limitations analysis. Most states have 2-4 year limitations periods. The discovery rule applies — limitations begins when patient knew or should have known about the connection to Allergan implants. Cases involving recent BIA-ALCL diagnosis or recent symptom development may qualify for discovery rule extension even with older implantation dates.

How Allergan compares to other ongoing mass torts

The litigation has distinctive features:

Compared to Bard hernia mesh MDL 2846 with $1+ billion settlement: Both involve medical device litigation. Bard hernia mesh reached global settlement; Allergan faces substantial preemption challenge specific to PMA-approved devices.

Compared to Bard PowerPort MDL 3081 with bellwethers beginning: Both have active bellwether activity. PowerPort uses 510(k) clearance (no Lohr preemption); Allergan uses PMA (Riegel preemption applies). Substantially different preemption posture.

Compared to Exactech device recall MDL 3044 affected by bankruptcy: Both involve recalled medical devices. Exactech bankruptcy froze litigation; Allergan has substantial financial capacity (parent AbbVie) for settlement.

Compared to Philips CPAP MDL 3014 with $1.1 billion settlement: Both involve medical device manufacturer recalls. Philips faced 510(k) clearance issues; Allergan faces PMA preemption.

Compared to Truvada/Tenofovir litigation with unusual procedural posture: Both involve substantial corporate financial capacity. Allergan has formal MDL; Truvada uses organic MDL plus state coordinated proceeding.

Compared to NEC infant formula MDL 3026 with state court success: Both involve substantial state court parallel proceedings. NEC has substantial state court verdicts; Allergan has parallel New Jersey state court litigation.

Distinctive Allergan features:

Bifurcated MDL track for cancer vs. non-cancer injuries
Substantial PMA preemption defense
AbbVie parent company financial capacity
International regulatory action preceding U.S. action
84% of worldwide BIA-ALCL cases involved Allergan products
Worldwide recall of substantial product line
Specific cancer (BIA-ALCL) with relatively clear diagnostic criteria

The broader procedural framework for mass tort settlements is detailed in our overview of how mass tort litigation works. Allergan represents medical device mass tort with substantial preemption considerations and bifurcated procedural framework.

Settlement projections

Settlement valuation depends substantially on bellwether outcomes:

BIA-ALCL cases (cancer track):

Strong scientific basis for causation
FDA acknowledgment of risk
Substantial documented injuries
Estimated settlement ranges:
- Mild cases (surgery only, full recovery): $150,000-$500,000
- Moderate cases (surgery + chemo, recovery): $500,000-$1,500,000
- Severe cases (advanced disease, permanent impact): $1,500,000-$5,000,000+
- Wrongful death cases: $1,000,000-$10,000,000+

Non-cancer cases (systemic injury track):

More challenging scientific causation
Less established medical recognition
Variable injury severity
Estimated settlement ranges:
- Mild cases: $25,000-$100,000
- Moderate cases: $100,000-$300,000
- Severe cases: $300,000-$1,000,000+

Prophylactic removal cases:

Limited damages (cost of explant)
May be addressed through warranty program
Settlement ranges: $25,000-$100,000

Tax implications. Personal injury settlements for physical injuries are generally tax-free under IRC §104(a)(2). But specific components may be taxable. Coordination with tax counsel is appropriate for substantial settlements, particularly when other tax debt issues or Voluntary Disclosure Practice considerations exist.

AbbVie financial capacity. AbbVie's substantial financial position (over $50 billion annual revenue) provides capacity for substantial global settlement framework. Final settlement timing depends on bellwether outcomes and preemption ruling.

Strategic considerations

For affected patients and prospective plaintiffs:

Identify your implant. Critical first step:

Check medical records for implant identification
Contact original surgeon for records
Hospital may have records identifying specific product
Recall notification letters confirm Biocell status

Consider BIA-ALCL surveillance. Even without symptoms, patients with Allergan Biocell implants should:

Discuss with healthcare provider
Monitor for symptoms (swelling, pain, lumps)
Consider periodic imaging
Maintain awareness of recurrence possibility if previously treated

For symptomatic patients:

Seek medical evaluation immediately
Document all symptoms
Pursue specific diagnostic testing if BIA-ALCL suspected
Don't delay treatment for legal considerations

Document the medical timeline comprehensively. The strongest cases include:

Original implantation operative report
Allergan product identification (style and lot number)
Complete medical records from implantation through current
Diagnosis documentation if BIA-ALCL or other injury
Treatment records (surgery, chemotherapy, radiation)
Surveillance records
Lost wages documentation

Engage experienced mass tort counsel. The MDL is procedurally complex with substantial preemption issues. Counsel with established Allergan case experience handles these cases substantially better. Most firms work on contingency basis (typically 30-40% of recovery).

Address the preemption issue. The pending preemption ruling will substantially affect:

Strength of remaining cases
Settlement framework
Strategic options

Monitor developments through counsel.

Choose track appropriately. BIA-ALCL track and non-cancer track have different procedural frameworks. Counsel should identify which track is appropriate for your specific case.

Plan for extended timeline. Bellwether trials beginning June 2026. Global settlement (if reached) likely 2027-2029. Plan for extended timeline.

Consider state court alternatives. Some plaintiffs may benefit from New Jersey state court filings rather than MDL participation. The procedural analysis depends on specific case facts.

Don't accept inadequate Allergan warranty alone. Allergan's "warranty" provides free implant replacement but doesn't compensate for:

Surgery costs for removal
Medical monitoring
Pain and suffering
Lost wages
Cancer treatment costs

The warranty is substantially inadequate for affected patients with substantial damages.

Coordinate with treating oncologists and surgeons. Plastic surgeons (original implantation), oncologists (BIA-ALCL diagnosis and treatment), and other treating physicians are important witnesses. Their support for the case theory strengthens cases.

Watch for wrongful death framework. Some BIA-ALCL plaintiffs have died from the cancer. Estates can pursue wrongful death claims with separate procedural framework.

Address tax planning for substantial settlements. Personal injury settlements for physical injuries are tax-free under §104(a)(2). Specific component allocation (physical injury vs. emotional distress vs. punitive) affects tax treatment. Coordinate with tax counsel for substantial settlements.

Plan for medical monitoring needs. BIA-ALCL surveillance is ongoing for patients with current or former Biocell implants. Even after settlement, medical monitoring may continue for years.

Consider both filing in MDL and explant decision. Some patients defer explant decision pending legal/medical evaluation. Others pursue immediate explant for medical reasons. Coordinate medical and legal decisions appropriately.

Don't delay claims unnecessarily. Statute of limitations periods are running. Discovery rule provides some flexibility, but cases involving older implantations and recent diagnoses benefit from prompt evaluation.

The Allergan Biocell textured breast implant litigation represents one of the more complex active medical device mass torts due to the combination of bifurcated MDL structure, substantial PMA preemption issues, and the relatively rare but serious BIA-ALCL cancer at the center of the litigation. The substantive case theory has substantial scientific support — FDA acknowledgment of risk, international regulatory actions preceding U.S. action, 84% of worldwide BIA-ALCL cases involving Allergan products, and internal corporate knowledge documented through discovery. The preemption defense is substantial but plaintiffs have plausible parallel claim theories that should survive preemption challenges. The June 2026 bellwether trial start and subsequent trials through 2027 will substantially determine settlement framework. For affected patients with documented Biocell implants and substantial injuries (especially BIA-ALCL diagnoses), the framework provides paths to meaningful compensation that should produce substantial outcomes once procedural complications resolve and bellwether trials provide settlement leverage. The work for plaintiffs is in comprehensive medical documentation including specific implant identification, engagement with experienced counsel familiar with both MDL practice and PMA preemption issues, careful coordination of medical and legal timelines, patient navigation of the bifurcated track structure, and informed monitoring of bellwether and preemption ruling developments. For plaintiffs with strong documented BIA-ALCL cases, the eventual resolution should produce settlement values reflecting the serious nature of the cancer caused by the alleged design defects in Allergan's Biocell textured breast implants.